Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02080780Phase 1Completed

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

Role: lead

NCT01355874Phase 3Terminated

Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids

Role: lead

NCT01690221Phase 3Completed

Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Role: lead

NCT01483833Phase 2Completed

Efficacy Study of Iferanserin to Treat Hemorrhoids

Role: lead

NCT01816529Phase 1Unknown

Topical Safety Study of Topical Diltiazem Hydrochloride

Role: lead

NCT01821274Phase 1Unknown

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

Role: lead

NCT01816191Phase 1Unknown

An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride

Role: lead

All 7 trials loaded